Amir Dagan

Amir Dagan

Auto-generated profile, based on publicly available information

Amir Dagan

Department of Internal Medicine 'B', Assuta Ashdod Medical Center, Ashdod, Israel

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JSJotham Suez
Jotham Suez
SPSteffen Porwollik
Steffen Porwollik
ADAmir Dagan
Amir Dagan
AMAlex Marzel
Alex Marzel
YSYosef Ilan Schorr
Yosef Ilan Schorr
OGOhad Gal-Mor
Ohad Gal-Mor
Human infection with non-typhoidal Salmonella serovars (NTS) infrequently causes invasive systemic disease and bacteremia. To understand better the nature of invasive NTS (iNTS), we studied the gene content and the pathogenicity of bacteremic strains from twelve serovars (Typhimurium, Enteritidis, Choleraesuis, Dublin, Virchow, Newport, Bredeney, Heidelberg, Montevideo, Schwarzengrund, 9,12:l,v:- and Hadar). Comparative genomic hybridization using a Salmonella enterica microarray revealed a core of 3233 genes present in all of the iNTS strains, which include the Salmonella pathogenicity islands 1–5, 9, 13, 14; five fimbrial operons (bcf, csg, stb, sth, sti); three colonization factors (misL, bapA, sinH); and the invasion gene, pagN. In the iNTS variable genome, we identified 16 novel genomic islets; various NTS virulence factors; and six typhoid-associated virulence genes (tcfA, cdtB, hlyE, taiA, STY1413, STY1360), displaying a wider distribution among NTS than was previously known. Characterization of the bacteremic strains in C3H/HeN mice showed clear differences in disease manifestation. Previously unreported characterization of serovars Schwarzengrund, 9,12:l,v:-, Bredeney and Virchow in the mouse model showed low ability to elicit systemic disease, but a profound and elongated shedding of serovars Schwarzengrund and 9,12:l,v:- (as well as Enteritidis and Heidelberg) due to chronic infection of the mouse. Phenotypic comparison in macrophages and epithelial cell lines demonstrated a remarkable intra-serovar variation, but also showed that S. Typhimurium bacteremic strains tend to present lower intracellular growth than gastroenteritis isolates. Collectively, our data demonstrated a common core of virulence genes, which might be required for invasive salmonellosis, but also an impressive degree of genetic and phenotypic heterogeneity, highlighting that bacteremia is a complex phenotype, which cannot be attributed merely to an enhanced invasion or intracellular growth of a particular strain.


1 June 2019 in Autoimmunity Reviews
Verified
Journal Article
Closed access
ADAmir Dagan
Amir Dagan
PLPnina Langevitz
Pnina Langevitz
YSYehuda Shoenfeld
Yehuda Shoenfeld
OSOra Shovman
Ora Shovman

1 March 2020 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
IGIdan Goren
Idan Goren
ABAdi Brom
Adi Brom
HYHenit Yanai
Henit Yanai
ADAmir Dagan
Amir Dagan
GSGad Segal
Gad Segal
AIAriel Israel
Ariel Israel
Background: Patients with inflammatory bowel disease might be at increased risk of invasive bacterial infections.Objectives: The objective of this study was to identify the rate of bacteremia in hospitalised patients with inflammatory bowel disease and risk factors.Methods: An observational cohort of hospitalised patients with inflammatory bowel disease, aged 16–80 years, from 2008 to 2017 in a large tertiary hospital. Patients with Charlson comorbidity index of 2 or greater were excluded. Patients with one or more positive blood culture were reviewed. Logistic regression was used to evaluate risk factors for bacteremia.Results: Of 5522 admitted patients, only 1.3% had bacteremia (73/5522) (39, Crohn’s disease; 25, ulcerative colitis; nine, unclassified inflammatory bowel disease). The most common pathogen was Escherichia coli (19/73 patients). The mortality rate at 30 days of patients with bacteremia was 13.7% (10/73). Longer hospitalisations (mean length of stay (21.6 ± 31.0 vs. 6.4 ± 16.0 days; P < 0.0001) and older age (mean age 47.5 ± 18.0 vs. 40.2 ± 15.4 years, P < 0.0001)) were associated with an increased risk of bacteremia. In multivariate analysis, treatment with either anti‐tumour necrosis factor α, purine analogues, steroids or amino salicylates was not associated with an increased risk of bacteremia. Risk was greatest among patients aged 65 years or older (relative risk 2.84, 95% confidence interval 1.6–4.8; P = 0.0001) relative to those under 65 years.Conclusion: Age over 65 years, but not inflammatory bowel disease‐related medications, is associated with an increased risk of bacteremia in hospitalised patients with inflammatory bowel disease.

1 January 2016 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
ADAmir Dagan
Amir Dagan
IGIrina Gringouz
Irina Gringouz
IKIris Kliers
Iris Kliers
GSGad Segal
Gad Segal
Dagan A, et al. J Clin Neurol. 2016 Jul;12(3):345-350. https://doi.org/10.3988/jcn.2016.12.3.345

1 October 2018 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
GZGuy Zamir
Guy Zamir
YHYael Haviv-Yadid
Yael Haviv-Yadid
KSKassem Sharif
Kassem Sharif
NBNicola Luigi Bragazzi
Nicola Luigi Bragazzi
AWAbdulla Watad
Abdulla Watad
OSOra Shovman
Ora Shovman